Novartis – science based innovation for better patient outcomes

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

Content from this campaign

Health & Healthcare
Asian Malaria Endgame Threatened by Resistance to Insecticides and Malaria Treatments
Asian malaria experts surveyed in a new report are saying that new tools are needed as the disease is becoming resistant to existing prevention and therapy measures. They called for continued investment in R&D for new antimalarials and insecticides to achieve the World Health Organization’s 2030 elimination targets.
Health & Healthcare
Europe-Africa Partnership Spearheads Development of Next-generation Antimalarial Drug
Health & Healthcare
Novartis Joins the Global Chagas Disease Coalition and Also Announces First Multinational, Prospective, Randomized Study in People With Chronic Chagas Cardiomyopathy
At the Annual Meeting of the Global Chagas Disease Coalition in Barcelona, Spain, Novartis announced that it is joining the Coalition as a member contributor. In addition, the company announced its commitment to launch a multinational, prospective, randomized study with heart failure drug, Entresto® (sacubitril / valsartan), in people with chronic Chagas cardiomyopathy, one form of heart failure with reduced ejection fraction. This is the first definitive morbidity and mortality study to assess a potential therapy for cardiac disease in this underserved patient population.
Health & Healthcare
Novartis Announces Five Grant Recipients of Excellence in Ophthalmology Vision Award (Xova) for Nonprofit Sustainable Eye Health Initiatives
Novartis announced the winners of the 2018 eXcellence in Ophthalmology Vision Award (XOVA) for nonprofit eye health initiatives at EURETINA 2018. The 2018 XOVA winners will help create sustainable eye clinics, train healthcare professionals, fight childhood blindness and increase eye health awareness in rural populations.

Health & Healthcare
Novartis Renews Drug Donation of Egaten® (Triclabendazole) Until 2022, Reaffirming Its Commitment to the Fight Against Liver Fluke
Novartis reaffirms its commitment to the fight against liver fluke (fascioliasis), signing a renewed memorandum of understanding with the World Health Organization (WHO) to extend its drug donation for Egaten® (triclabendazole) until 2022. Egaten is currently the only treatment for fascioliasis recommended by the WHO and is on the WHO Model List of Essential Medicines.
Health & Healthcare
Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globally
Alcon, the global leader in eye care and a division of Novartis, today announced Alcon Cares Project 100, which aims to reduce cataract blindness by providing equipment to perform phacoemulsification (or “phaco”), a key step in the cataract surgery procedure. Alcon Cares, a foundation that oversees equipment and product donations to those in need, will give 100 reprocessed Infiniti units to eligible clinics in Asia, Central and South America, and Africa over the next three years, making it one of the largest eye care equipment donations of its kind.
Health & Healthcare
Novartis Foundation Announces Implementation Partners for Better Hearts Better Cities Urban Health Initiative in São Paulo, Brazil
Less than three months after the selection of São Paulo, Brazil as the third city of the urban health initiative Better Hearts Better Cities, the Novartis Foundation announced the creation of a network of global and local implementation partners. They will co-design interventions to address São Paulo’s urban priorities to improve local cardiovascular health, including health education, lifestyle community programs, care coordination and standardization according to up-to-date clinical guidelines, and incorporating digital health tools into screening and care for high blood pressure.
Media & Communications
Novartis Forms Alliance to Develop Medicines for Treating Infectious Diarrheal Disease
Novartis receives funding from Bill & Melinda Gates Foundation for further development of Novartis drug candidate KDU731 for the treatment of cryptosporidiosis
Health & Healthcare
Novartis Foundation Aims to Improve Cardiovascular Health as the Better Hearts Better Cities Initiative Gains Momentum Announcing New Partners and Confirming São Paulo as the Third City
Less than a year since its launch, the Novartis Foundation urban initiative, Better Hearts Better Cities, has made significant progress in mobilizing a broad network of partners and developing a framework for action to improve cardiovascular health across the selected cities.
Health & Healthcare
World Heart Day 2017 – a Global Vision for Healthy Hearts
Cardiovascular diseases, including hypertension, account for nearly half of the world’s deaths from non-communicable diseases (NCDs). With almost 75% of NCD deaths occurring in LMICs, the Novartis Foundation recognizes the importance of World Heart Day in raising awareness of cardiovascular disease and promoting good heart health globally.

More from Novartis

The Novartis Malaria Initiative

For over a decade, the Novartis Malaria Initiative has been a pioneer in the fight against malaria. Focused on access, treatment, R&D and capacity...